The Prince Charles Hospital
Welcome,         Profile    Billing    Logout  
 29 Trials 
79 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Marshall, John L
NCT03950817: Nebulized Sub-dissociative Dose Ketamine at Three Different Dosing Regimens for Treating Acute Pain in the Pediatric ED

Completed
4
80
US
Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg, Nebulized Sub-dissociative Dose Ketamine at 1 mg/kg, Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
Antonios Likourezos
Pain
09/24
09/24
ARBs CORONA II, NCT04606563: Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

Terminated
3
341
Europe, Canada
Losartan, Cozaar, Valsartan, Diovan, Azilsartan, Edarbi, Candesartan, Atacand, Eprosartan, Teventen, Irbesartan, Avapro, Olmesartan, Olmetec, Telmisartan, Micardis
University of British Columbia, Canadian Institutes of Health Research (CIHR)
Covid19, SARS-CoV Infection
04/22
04/22
REVISE, NCT03374800 / 2020-000483-27: Re-EValuating the Inhibition of Stress Erosions () Trial

Completed
3
4800
Europe, Canada, US, RoW
Placebo (0.9% saline), normal saline; NaCl 0.9%, Pantoprazole, Protonix
McMaster University, Canadian Institutes of Health Research (CIHR), Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, National Health and Medical Research Council, Australia
Gastrointestinal Hemorrhage (Clinically Important, Upper)
10/23
01/24
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
MRD-GI, NCT05482516: Evaluating Novel Therapies in ctDNA Positive GI Cancers

Recruiting
3
20
US
Atezolizumab, TECENTRIQ, Bevacizumab, Avastin
Georgetown University, Genentech, Inc., Natera, Inc.
Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma
12/26
12/28
RADAR-Canada, NCT06326112: Role of Active Deresuscitation After Resuscitation:

Not yet recruiting
2
120
Canada
Furosemide Injection, Metolazone Tablets
Unity Health Toronto, Canadian Institutes of Health Research (CIHR)
Fluid Overload, Critical Illness, Sepsis, ARDS, Trauma
03/25
06/25
Proton-PANC, NCT03885284: Study of Proton Therapy in Adjuvant Pancreatic Cancer

Completed
1
9
US
mFOLFIRINOX, Proton beam radiation
Georgetown University
Resected Pancreatic Adenocarcinoma
05/22
11/23
NCT01428089: Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone

Recruiting
1
40
US
Progesterone, Placebo
University of Virginia, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Polycystic Ovary Syndrome, Hyperandrogenism, Normal Puberty
12/24
12/24
NCT01422746: Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

Recruiting
1
20
US
Metformin, Glucophage
University of Virginia
Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
12/24
12/24
CRM009, NCT03401047: Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Recruiting
1
37
US
Estradiol, Vivelle
University of Virginia
Polycystic Ovary Syndrome
04/25
12/25
BALANCE, NCT03005145: Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

Completed
N/A
3622
Europe, Canada, US, RoW
7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment.
Sunnybrook Health Sciences Centre
Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial
05/23
08/23
NanoCOAT, NCT04717024: The Nanowear Wearable Covid-19 Observational and Analysis Trend

Recruiting
N/A
100
US
Observational Study - no intervention
Nanowear Inc.
Covid19
12/23
12/23
SODA-SWAP, NCT06427915: Studying Glucose and Appetite Response With Alternatives to Soda Pop

Recruiting
N/A
30
US
OLIPOP prebiotic soda, Traditional sugar-sweetened cola
Olipop, PBC, BioFortis
Healthy Nutrition
07/24
08/24
NCT05473702: Smart Textile Sensor System for Health Monitoring

Recruiting
N/A
200
US
Nanowear SimpleSense Wearable monitoring device
Nanowear Inc.
Heart Disease Chronic, Pulmonary Disease, Chronic Obstructive, Blood Pressure, Heart Rhythm Disorder
06/24
06/24
NCT01421797: Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation

Active, not recruiting
N/A
84
US
Dexamethasone, Cortrosyn, ACTH
University of Virginia, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of California, San Diego
Hyperandrogenemia, Polycystic Ovary Syndrome, Obesity
08/24
12/24
NCT01422759: Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

Recruiting
N/A
20
US
Spironolactone, Aldactone
University of Virginia
Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
12/24
12/24
NCT02155933: Assessment of Day-night Secretion of Progesterone and LH Across Puberty

Recruiting
N/A
75
US
Blood sampling
University of Virginia, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Puberty, Hyperandrogenism
02/25
02/25
NCT01650311: Investigating Serotonin Signalling in IBD Patients

Recruiting
N/A
60
Canada
McMaster University
Inflammatory Bowel Disease
05/25
05/25
ARBS CORONA I, NCT04510623: Host Response Mediators in Coronavirus (COVID-19) Infection

Recruiting
N/A
500
Canada
ARBs and/or ACE inhibitors, Usual Care
University of British Columbia, Canadian Institutes of Health Research (CIHR), British Columbia Centre for Disease Control, McGill University Health Centre/Research Institute of the McGill University Health Centre, University of Toronto, University of Ottawa, University of Calgary, University of Alberta, University of Victoria, Wuhan University, Peking Union Medical College, University of Pennsylvania
COVID-19, SARS-CoV2
06/21
06/22
Douglas, James G
CATCO, NCT04330690: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Active, not recruiting
3
2900
Canada
Artesunate, Imatinib, Infliximab, Dexamethasone, LSALT Peptide
Sunnybrook Health Sciences Centre, AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc.
COVID-19
03/24
05/24
BALANCE, NCT03005145: Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

Completed
N/A
3622
Europe, Canada, US, RoW
7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment.
Sunnybrook Health Sciences Centre
Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial
05/23
08/23
Chambers, Daniel
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
08/25
06/27
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Active, not recruiting
3
597
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
07/25
07/25
SiroSkin, NCT05860881: Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients

Recruiting
3
146
RoW
Sirolimus Topical Cream, Rapamycin, Placebo, Vehicle alone
Melanoma and Skin Cancer Trials Limited, Monash University, The University of Queensland
Solid Organ Transplant Recipients, Skin Cancer
05/26
12/26
SPARTA, NCT01983241 / 2013-001870-38: Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

Active, not recruiting
3
345
Europe, Canada, US, RoW
Alpha-1 MP, Prolastin-C, 0.9% Sodium Chloride for Injection, USP, Saline
Grifols Therapeutics LLC
Pulmonary Emphysema in Alpha-1 PI Deficiency
08/26
01/27
ASSIST-CLAD, NCT02709343: Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction

Completed
2
64
RoW
Bone-marrow derived MSCs, MSC, Placebo
The University of Queensland, Isopogen, Cell and Tissue Therapies
Chronic Lung Allograft Dysfunction (CLAD)
09/23
10/23
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

Active, not recruiting
2
99
Europe, US, RoW
SAR447537, Zemaira, Respreeza
Sanofi
Alpha 1-Antitrypsin Deficiency, Emphysema
08/25
10/25
SHIELD, NCT05402176: The Whole Lung Lavage Study

Not yet recruiting
N/A
30
RoW
Whole Lung Lavage
The University of Queensland
Silicosis
06/24
12/24
SHIELD, NCT05546944: The Study-silicosis

Recruiting
N/A
120
RoW
The University of Queensland, The Prince Charles Hospital, Royal Prince Alfred Hospital, Sydney, Australia, The Alfred, Austin Hospital, Melbourne Australia
Silicosis
06/24
12/24
Henderson, Robert
AIDE T1D, NCT04016662: Automated Insulin Delivery in Elderly With Type 1 Diabetes

Completed
4
82
US
Tandem t:slim X2 with HCL or PLGS, Tandem t:slim X2 with Control-IQ Technology, Tandem t:slim X2 with Basal-IQ Technology
Jaeb Center for Health Research, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), DexCom, Inc., Tandem Diabetes Care, Inc., University of Minnesota - Advanced Research and Diagnostic Laboratory, Mayo Clinic, University of Pennsylvania, AdventHealth Diabetes Institute, Washington State University
Type 1 Diabetes Mellitus
09/23
01/24
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Terminated
3
71
Europe, Canada, US, RoW
Reldesemtiv
Cytokinetics, Cytokinetics Inc
Amyotrophic Lateral Sclerosis
06/23
06/23
IBM-FRS, NCT04789070: Phase III Trial of Sirolimus in IBM

Recruiting
3
140
US, RoW
Sirolimus, Rapamune, Placebo
University of Kansas Medical Center, The Perron Institute
Inclusion Body Myositis
09/26
09/26
ATS23, NCT06380517: Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age

Recruiting
3
238
US
Luminopia, Eye Patch
Jaeb Center for Health Research, National Eye Institute (NEI), Pediatric Eye Disease Investigator Group
Amblyopia
12/26
05/27
Lighthouse III, NCT06658977: RolloverTreatment with Triumeq for People with ALS Following the Lighthouse II Trial

Not yet recruiting
3
70
RoW
Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)
Macquarie University, Australia
Amyotrophic Lateral Sclerosis, ALS
12/26
12/26
LIGHTHOUSE II, NCT05193994: Triumeq in Amyotrophic Lateral Sclerosis

Active, not recruiting
3
390
Europe, RoW
Dolutegravir, Abacavir and Lamivudine, Triumeq, Placebo
Macquarie University, Australia, King's College London, Stichting TRICALS Foundation
Amyotrophic Lateral Sclerosis
08/26
08/26
Fortify, NCT05775848: Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Active, not recruiting
3
81
Europe, US, RoW
BBP-418 (ribitol), Placebo
ML Bio Solutions, Inc.
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
07/27
07/27
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
MetFlex, NCT04788745: Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)

Completed
2
21
Europe, RoW
Trimetazidine Dihydrochloride
The University of Queensland, FightMND, UMC Utrecht, King's College London, Julius Clinical
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
05/23
05/23
REAL, NCT05218668: Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis

Active, not recruiting
2
40
US, RoW
Fasudil (WP-0512)
Woolsey Pharmaceuticals
Amyotrophic Lateral Sclerosis
07/26
01/28
NCT05791864: A First-in-Human Study in Pediatric Patients With Ocular CLN2 Disease

Active, not recruiting
1/2
4
Europe
RGX-381, Gene Therapy (AAV9.CB7.hCLN2)
Tern Therapeutics, LLC
Neuronal Ceroid Lipofuscinosis Type 2
07/26
07/29
NCT04659031: A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)

Active, not recruiting
1
30
RoW
ABC008
Abcuro, Inc.
Inclusion Body Myositis
03/25
08/25
Fowler, Rob A
REVISE, NCT03374800 / 2020-000483-27: Re-EValuating the Inhibition of Stress Erosions () Trial

Completed
3
4800
Europe, Canada, US, RoW
Placebo (0.9% saline), normal saline; NaCl 0.9%, Pantoprazole, Protonix
McMaster University, Canadian Institutes of Health Research (CIHR), Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, National Health and Medical Research Council, Australia
Gastrointestinal Hemorrhage (Clinically Important, Upper)
10/23
01/24
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
BALANCE, NCT03005145: Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

Completed
N/A
3622
Europe, Canada, US, RoW
7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment.
Sunnybrook Health Sciences Centre
Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial
05/23
08/23
SIMPLY-SNAP, NCT06168474: Evaluating Simplified Layered Consent for Clinical Trials

Recruiting
N/A
346
Canada
Simplified layered consent form, Full-length consent form
Sunnybrook Health Sciences Centre, McGill University Health Centre/Research Institute of the McGill University Health Centre
Staphylococcus Aureus Bacteremia
06/25
06/25
REVIVe, NCT05246098: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or ARI

Recruiting
N/A
900
Canada
McMaster University, Canadian Institutes of Health Research (CIHR), Canadian Critical Care Trials Group
Respiratory Disease, COVID-19, Viral Infection
03/25
10/25
NCT06537609: A Platform Trial for Gram Negative Bloodstream Infections

Recruiting
N/A
2500
Canada
De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement, Cephalosporin VS Carbapenem for low risk AmpC organisms, Routine follow-up blood culture VS No routine follow-up blood culture
Sunnybrook Health Sciences Centre, Canadian Institutes of Health Research (CIHR)
Gram-negative Bacteremia
04/27
04/28
SPRINT-SARI, NCT02498587: Short Period Incidence Study of Severe Acute Respiratory Illness

Recruiting
N/A
15000
RoW
Australian and New Zealand Intensive Care Research Centre, International Severe Acute Respiratory and Emerging Infection Consortium, The International Forum of Acute Care Trialists
Severe Acute Respiratory Infection
12/26
12/26
BALANCE+, NCT05893147: Vanguard Phase

Completed
N/A
174
Canada
De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement, Cephalosporin VS Carbapenem for low risk AmpC organisms, Routine follow-up blood culture VS No routine follow-up blood culture
Sunnybrook Health Sciences Centre, Canadian Institutes of Health Research (CIHR)
Gram-negative Bacteremia
07/24
08/24
Fraser, John J
ROCKY REHAB, NCT04999904: A Proprioceptive Training Program Using an Uneven Terrain Treadmill for Patients With Ankle Instability

Recruiting
N/A
312
US
Uneven Treadmill Intervention, Standard of Care Physical Therapy
Henry M. Jackson Foundation for the Advancement of Military Medicine, Extremity Trauma and Amputation Center of Excellence, United States Naval Medical Center, San Diego, Madigan Army Medical Center, Fort Sam Houston, Naval Hospital Camp Pendleton, Naval Health Research Center, Veterans Affairs Puget Sound Health Care System
Instability; Ankle (Ligaments) (Old Injury), Sprain of Ankle
03/23
09/24
REDEEM, NCT05562505: Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure

Recruiting
N/A
140
Europe, RoW
Venovenous ECMO
Australian and New Zealand Intensive Care Research Centre, The Alfred
Mechanical Ventilation Complication, Hypoxemia, Acute Respiratory Distress Syndrome Due to COVID-19, COVID-19 Respiratory Infection, Pneumonia, Extracorporeal Membrane Oxygenation
07/26
01/27
NCT03793257: The EXCEL Registry of Patients Requiring ECMO

Recruiting
N/A
3000
RoW
Australian and New Zealand Intensive Care Research Centre, National Health and Medical Research Council, Australia, Extracorporeal Life Support Organization, National Heart Foundation, Australia, The Alfred, Barwon Health, Fiona Stanley Hospital, The Prince Charles Hospital, Royal Prince Alfred Hospital, Sydney, Australia, St Vincent's Hospital, Sydney
Critically Ill, Acute Respiratory Failure, Acute Heart Failure, Cardiac Arrest
12/26
12/27
Fong, Kwun M
NCT02871856: International Lung Screen Trial (ILST)

Active, not recruiting
N/A
2000
Canada, RoW
Low dose CT
The University of Queensland
Non-small Cell Lung Cancer, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases, Smokers at Risk of Lung Cancer
12/25
12/25
ACTRN12610000007033: Low dose Computed Tomography (CT) screening for lung cancer

Recruiting
N/A
750
 
The Prince Charles Hospital (TPCH), National Center for Asbestos Related Disease (NCARD), Queensland Smart State
lung cancer
 
 
Walters, Darren
VISTA, NCT05797519: Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation

Recruiting
N/A
40
Europe, RoW
VDyne Transcatheter Tricuspid Valve Replacement System, VDyne System, VDyne Tricuspid System, VDyne Valve System, VDyne Valve
VDyne, Inc.
Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
09/25
09/29
McKenzie, Scott
NCT05425459: RESPONDER-HF Trial

Recruiting
N/A
750
Europe, Canada, US, RoW
Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
Corvia Medical
Heart Failure, Heart Failure, Diastolic
05/25
03/31
Enever, Debra
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Active, not recruiting
3
597
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
07/25
07/25
Hopkins, Peter
TFF-T2-001, NCT05501574: An Open Label Trial Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetic Profile of Tacrolimus Inhalation Powder in Adult Lung Transplant Recipients

Terminated
2
14
RoW
Tacrolimus Inhalation Powder, Tacrolimus, Plastiape RS00 Dry Powder inhaler device
TFF Pharmaceuticals, Inc., Novotech (Australia) Pty Limited
Lung Transplant Rejection
10/24
12/24
Reid, David
TEMPO, NCT04014179: Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs

Recruiting
N/A
2700
RoW
Xpert HCV Viral Load Fingerstick, Aptima HCV Quant DX Assay
Kirby Institute
Hepatitis C, Hepatitis C, Chronic
12/25
12/25
NCT05042544: The National Australian HCV Point-of-Care Testing Program

Recruiting
N/A
40000
RoW
Point-of-Care Testing
Kirby Institute, Flinders University
Hepatitis C
12/24
12/26
Mackintosh, John
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Active, not recruiting
3
597
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
07/25
07/25
ACTRN12620001363976p: The TELO-SCOPE Study: Attenuating Telomere Attrition with Danazol. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis?

Not yet recruiting
2
50
 
The University of Queensland, Australian Government Department of Health, Medical Research Future Fund
Pulmonary fibrosis associated with age adjusted telomere length less than the 10th centile.
 
 
ACTRN12620001363976: The TELO-SCOPE Study: Attenuating Telomere Attrition with Danazol. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis?

Recruiting
2
50
 
The University of Queensland, Australian Government Department of Health, Medical Research Future Fund
Pulmonary fibrosis associated with age adjusted telomere length less than the 10th centile.
 
 
TELO-SCOPE, NCT04638517: The Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis

Recruiting
2
50
RoW
Danazol, Placebo
The University of Queensland
Pulmonary Fibrosis, Telomere Shortening, Telomere Disease, Dyskeratosis Congenita
12/24
06/25
NCT05331300: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

Completed
1/2
75
RoW
LASN01, Placebo
Lassen Therapeutics 1 PTY LTD
Pulmonary Fibrosis, Thyroid Eye Disease
11/24
11/24
Bennetts, Jayme
VISTA, NCT05797519: Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation

Recruiting
N/A
40
Europe, RoW
VDyne Transcatheter Tricuspid Valve Replacement System, VDyne System, VDyne Tricuspid System, VDyne Valve System, VDyne Valve
VDyne, Inc.
Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
09/25
09/29
Pearse, Bronwyn
CLIP II, NCT03991481: The Cryopreserved vs. Liquid Platelets Trial

Active, not recruiting
3
388
RoW
Cryopreserved platelets, Liquid-stored platelets
Australian and New Zealand Intensive Care Research Centre, Australian Red Cross
Surgical Blood Loss, Hemorrhage
07/24
11/25
Kewalram, Gurudev
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
Curtin, Deanne
3TLA, NCT05136222: Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease

Recruiting
N/A
244
RoW
Intervention polysomnography, Sham polysomnography
University of Melbourne, Austin Hospital, Melbourne Australia, Institute for Breathing and Sleep, Australia, Royal Prince Alfred Hospital, Sydney, Australia, Macquarie University, Australia, Macquarie Health, Western Sydney Local Health District, Flinders Medical Centre, Sir Charles Gairdner Hospital, The Prince Charles Hospital, Monash University, Motor Neurone Disease Australia, FightMND, Australian Motor Neurone Disease Registry, Calvary Bethlehem, Perron Institute for Neurological and Translational Science
Motor Neuron Disease / Amyotrophic Lateral Sclerosis
02/26
02/28
Murdoch, Dale
NCT04091048: Optimize PRO Study

Active, not recruiting
N/A
800
Europe, Canada, US, RoW
Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)
Medtronic Cardiovascular
Symptomatic Aortic Stenosis
12/23
12/24
EASY-AS, NCT04204915: The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study

Recruiting
N/A
2844
Europe, RoW
Aortic valve replacement
University of Leicester, University of Auckland, New Zealand, University Hospitals, Leicester, The University of Western Australia
Aortic Stenosis
04/31
04/31
Matebele, Mbakise
CALIPSO, NCT05447559: Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study

Recruiting
4
9180
RoW
Cefazolin, Water for injection
Monash University, The Australian and New Zealand College of Anaesthetists (ANZCA)
Surgical Site Infection
01/27
06/27
O'Brien, Donalee
CALIPSO, NCT05447559: Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study

Recruiting
4
9180
RoW
Cefazolin, Water for injection
Monash University, The Australian and New Zealand College of Anaesthetists (ANZCA)
Surgical Site Infection
01/27
06/27
Gill, Denzil
STEPCARE, NCT05564754 / ACTRN12623001057673: Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation

Recruiting
N/A
3500
Europe, RoW
Feedback-controlled temperature device, High MAP, Deep sedation, Fever control without a device, Low MAP, Minimal sedation
Region Skane, Lund University, Lund, Sweden, Copenhagen Trial Unit, Center for Clinical Intervention Research, The George Institute for Global Health, Australia, HUS Helsinki University Hospitals, Helsinki, Finland, Medical Research Institute of New Zealand Rangahautia Te Ora, Wellington, New Zealand
Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain
12/25
06/26
Timmins, Sjane
NCT06122233: REBUILD-SM Study for People With Interstitial Lung Disease (ILD)

Recruiting
N/A
400
RoW
Pulmonary Fibrosis self-management package and smartphone application, REBUILD-SM
University of Sydney, Monash University, Lung Foundation Australia, University of Tasmania
Lung Diseases, Interstitial, Pulmonary Fibrosis
06/27
08/27
Tavolini, Dario
MyClad, NCT06463587: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis

Recruiting
3
240
Europe, Japan, US, RoW
Placebo, Cladribine Low Dose, Cladribine High Dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Generalized Myasthenia Gravis
05/28
07/30
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
Chien, Jimmy
ABCI, NCT05802264: Study to Assess Amphotericin B Cystetic for Inhalation () Doses in Healthy Volunteers & People With Cystic Fibrosis

Recruiting
1
84
RoW
ABCI, Amphotericin B Cystetic for Inhalation, Placebo
Cystetic Medicines, Inc., DevPro Biopharma
Cystic Fibrosis
12/24
12/24

Download Options